CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans

Impact · against what's priced in

CareDx is strategically pivoting toward high-margin precision diagnostics through the Naveris acquisition and the divestiture of its slower-growth lab products business. While the company shows strong volume growth in transplant testing, it faces a material near-term headwind from an estimated $15 million annualized reimbursement loss due to MolDx coverage changes.

CDNA+0.20

No priced-in read yet